REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who purchased Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before September 14, 2026. The Company made false and misleading statements to the market. Regeneron led investors to believe that its Phase III Fianlimab-Libtayo Study was likely to succeed by achieving its primary endpoint. The Company utilized flawed statistical assumptions. In fact, the Company failed to demonstrate clinical differentiation from other therapies. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Regeneron, investors suffered damages.